Commonwealth Equity Services’s Insight Molecular Diagnostics IMDX Stock Holding History

Commonwealth Equity Services’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,760	Closed	-$73K	–	2930
2019 Q3	$73K	Hold	1,760	–	–	﹤0.01%	2715
2019 Q2	$87K	Buy	1,760 +260	+17%	+$21.6K	﹤0.01%	2646
2019 Q1	$118K	Buy	1,500 +40	+3%	+$2.58K	﹤0.01%	2581
2018 Q4	$40K	Buy	1,460 +252	+21%	+$9.06K	﹤0.01%	2582
2018 Q3	$60K	Buy	+1,208	New	+$62.3K	﹤0.01%	2685

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Commonwealth Equity Services's IMDX Position: Q4 2019 in Review

Commonwealth Equity Services sold out of Insight Molecular Diagnostics (IMDX) in Q4 2019, closing a stake of 1,760 shares — an estimated $73K sold.

Commonwealth Equity Services first reported a position in IMDX in Q3 2018 and held it in 5 quarters. The position peaked at $118K in Q1 2019. 56 funds tracked by Wall St. Rank hold IMDX as of Q4 2019.

Commonwealth Equity Services reported no remaining Insight Molecular Diagnostics position as of Q4 2019 after selling out during the quarter.
Commonwealth Equity Services sold 1,760 Insight Molecular Diagnostics shares in Q4 2019, an estimated $73K.
Commonwealth Equity Services first reported a position in Insight Molecular Diagnostics in Q3 2018 and held it in 5 quarters.
Commonwealth Equity Services's Insight Molecular Diagnostics position peaked at $118K in Q1 2019.
56 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2019.

Based on Commonwealth Equity Services's 13F filing for Q4 2019, filed 5 Feb 2020.